NO20083709L - Nye krystallinske forbindelser - Google Patents

Nye krystallinske forbindelser

Info

Publication number
NO20083709L
NO20083709L NO20083709A NO20083709A NO20083709L NO 20083709 L NO20083709 L NO 20083709L NO 20083709 A NO20083709 A NO 20083709A NO 20083709 A NO20083709 A NO 20083709A NO 20083709 L NO20083709 L NO 20083709L
Authority
NO
Norway
Prior art keywords
acid
crystalline compounds
naphthalene
new crystalline
tartaric
Prior art date
Application number
NO20083709A
Other languages
English (en)
Inventor
Ulrike Werthmann
Uwe Ries
Sonja Sproll
Andreas Zopf
Guenther Huchler
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of NO20083709L publication Critical patent/NO20083709L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Reproductive Health (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Addiction (AREA)
  • Obesity (AREA)
  • Pregnancy & Childbirth (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Otolaryngology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)

Abstract

Oppfinnelsen angår de nye krystallinske forbindelser A med den generelle formel I: (I), hvor A1, A2, A3, X, Y1, Y2 og Y3 er definert som angitt i krav 1, og som tilveiebringes i form av de fysiologisk akseptable saltene derav med syrer, idet syrene som er valgt fra gruppe B omfatter saltsyre, bromhydrogensyre, svovelsyre, fosforsyre, benzensulfonsyre, p-toluensulfonsyre, maleinsyre, ravsyre, fumarsyre, D-(-)-vinsyre, L-(+)-vinsyre, naftalen-2-sulfonsyre og naftalen-1,5-disulfonsyre, så vel som polymorfene, de respektive solvatene og hydratene. 270 83
NO20083709A 2006-04-13 2008-08-28 Nye krystallinske forbindelser NO20083709L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102006017827A DE102006017827A1 (de) 2006-04-13 2006-04-13 Neue kristalline Verbindungen
PCT/EP2007/053488 WO2007118819A2 (de) 2006-04-13 2007-04-11 Neue kristalline verbindungen

Publications (1)

Publication Number Publication Date
NO20083709L true NO20083709L (no) 2008-10-31

Family

ID=38514672

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20083709A NO20083709L (no) 2006-04-13 2008-08-28 Nye krystallinske forbindelser

Country Status (20)

Country Link
US (1) US7638625B2 (no)
EP (1) EP2010513A2 (no)
JP (1) JP2009533387A (no)
KR (1) KR20090007428A (no)
CN (1) CN101421263A (no)
AR (1) AR060442A1 (no)
AU (1) AU2007239505A1 (no)
BR (1) BRPI0710151A2 (no)
CA (1) CA2648140A1 (no)
CO (1) CO6140057A2 (no)
DE (1) DE102006017827A1 (no)
EA (1) EA200802049A1 (no)
EC (1) ECSP088737A (no)
MX (1) MX2008013158A (no)
NO (1) NO20083709L (no)
PE (1) PE20080735A1 (no)
TW (1) TW200808767A (no)
UY (1) UY30280A1 (no)
WO (1) WO2007118819A2 (no)
ZA (1) ZA200806859B (no)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7491717B2 (en) * 2005-03-23 2009-02-17 Boehringer Ingelheim International Gmbh Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions
MX2008015562A (es) * 2006-06-08 2008-12-17 Boehringer Ingelheim Int Tratamiento de trastornos gastrointestinales con antagonistas de cgrp.
BR112014021032B1 (pt) * 2012-02-27 2022-09-27 Bristol-Myers Squibb Company Sal hemissulfato de n-(5s,6s,9r)-5-amino-6-(2,3-difluoro-fenil)-6,7,8,9-tetra-hidro-5h- iclohepta[b]piridin-9-il-4-(2-oxo-2,3-dihidro-1h-imidazo[4,5-b]piridin-1-il}-piperidina-1-carboxilato, seu uso e composição farmacêutica que o compreende

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EE04375B1 (et) 1996-09-10 2004-10-15 Dr. Karl Thomae Gmbh Modifitseeritud aminohapped, neid ühendeid sisaldavad ravimid ja nende valmistamise meetod
DE10250082A1 (de) * 2002-10-25 2004-05-13 Boehringer Ingelheim Pharma Gmbh & Co. Kg Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
DE10250080A1 (de) * 2002-10-25 2004-05-13 Boehringer Ingelheim Pharma Gmbh & Co. Kg Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
DE102004015723A1 (de) * 2004-03-29 2005-10-20 Boehringer Ingelheim Pharma Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel

Also Published As

Publication number Publication date
EP2010513A2 (de) 2009-01-07
JP2009533387A (ja) 2009-09-17
DE102006017827A1 (de) 2007-10-18
ECSP088737A (es) 2008-10-31
EA200802049A1 (ru) 2009-04-28
US7638625B2 (en) 2009-12-29
AU2007239505A1 (en) 2007-10-25
CA2648140A1 (en) 2007-10-25
WO2007118819A2 (de) 2007-10-25
MX2008013158A (es) 2008-10-22
BRPI0710151A2 (pt) 2011-08-02
ZA200806859B (en) 2009-08-26
US20080086003A1 (en) 2008-04-10
UY30280A1 (es) 2007-11-30
KR20090007428A (ko) 2009-01-16
TW200808767A (en) 2008-02-16
CO6140057A2 (es) 2010-03-19
CN101421263A (zh) 2009-04-29
PE20080735A1 (es) 2008-07-25
WO2007118819A3 (de) 2008-05-29
AR060442A1 (es) 2008-06-18

Similar Documents

Publication Publication Date Title
WO2007017728A3 (en) Novel heterocyclic compounds
TW200734038A (en) Novel dispersant and compositions thereof
NO20091782L (no) Fremgangsmate for syntese av derivater av 3-amino-tetrahydrofuran-3-karboxylsyre og deres anvendelse som medikamenter
AR075227A1 (es) Procedimiento de sintesis de ivabradina y sus sales de adicion de acidos farmaceuticamente aceptables.
NO20083709L (no) Nye krystallinske forbindelser
UA88643C2 (ru) Производные амида гетероциклической карбоновой кислоты
EA201270421A1 (ru) 1,2-дигидро-2-оксохинолиновые соединения в качестве лигандов рецептора 5-нт
NZ598354A (en) New process for the synthesis of ivabradine and addition salts thereof with a pharmaceutically acceptable acid
DE602006007483D1 (no)
MX2010009876A (es) Nuevo proceso para la preparacion de derivados de acido ciclohexanocarboxilico por medio del derivado de ciclohexanocarboxamida correspondiente.
NO20072755L (no) Fremgangsmate for fremstilling av 4-(6-klor-2-metylendioksyanilino)-7-2-(4-metylpiperazin-1-yl)etoksy]-5-tetrahydropyran-4-yloksykinazolin, deres mellomprodukter og krystallinske salter derav
Annedi et al. 3, 5-Disubstituted indole derivatives as selective human neuronal nitric oxide synthase (nNOS) inhibitors
WO2007105021A3 (en) Duloxetine salts
NO330989B1 (no) Nye piperazinderivater, fremgangsmater for fremstilling av slike og deres anvendelse som syntesemellomprodukter.
WO2007004041A3 (en) New compounds and their pharmaceutical use
BG108435A (en) Novel crystalline forms of 4-[4-[4-(hydroxydiphenyl methyl)-1-piperidinyl]-1-hydroxybutyl]-alpha, alpha-dimethylbenzene acetic acid and its hydrochloride
RS52529B (en) A NEW PROCEDURE FOR THE SYNTHESIS OF IVABRADINE AND ITS ADDED SALTS
WO2007135693A3 (en) Intermediates useful for the preparation of antihistaminic piperidine derivative
NO20070845L (no) Fremgangsmate for fremstilling av losartan
NO20070776L (no) Forbedret prosess for fremstilling av mirtazapin
MX2007000906A (es) Procedimiento para la preparacion de 3-(4-piperidinil) -2, 3, 4, 5-tetrahidro-1, 3-benzodiazepin -2(1h)-ona.
EA201170284A1 (ru) Синтез производных 3,4-диарил-4,5-дигидро-(1h)-пиразол-1-карбоксамидина
WO2006109146A3 (en) Novel heterocyclic derivatives
TW200732319A (en) 3-(4-piperidinyl)-2,3,4,5-tetrahydro-1,3-benzodiazepin-2(1H)-one
MX2010002300A (es) Polimorfos de sal sodica del acido (3-(((4-terc-butil-bencil)-(pir idin-3-sulfonil)-amino)-metil)-fenoxi)-acetico o un hidrato de los mismos y procedimientos para fabricar los mismos.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application